Table 3.
Unadjusted and Adjusted Event Rates by NOAC Dose Received (Rivaroxaban or Apixaban) Among Patients Recommended for Standard NOAC Dosing (n=6584)
| Overall (n=6584) | Unadjusted (n=6584) | Overlap Propensity Weighted | |||||
|---|---|---|---|---|---|---|---|
| Events (Rate Per 100 Patient‐Years) | Appropriate Standard (n=5895) | Inappropriately Reduced (n=689) | HRa (95% CI) | P Value | HRa (95% CI) | P Value | |
| Thromboembolic outcomes | |||||||
| Stroke, non‐CNS embolism, or TIA | 107 (1.43) | 91 (1.35) | 16 (2.11) | 1.56 (0.92‐2.67) | 0.1 | 1.11 (0.61‐2.02) | 0.7 |
| MI | 47 (0.62) | 41 (0.60) | 6 (0.78) | 1.29 (0.62‐2.69) | 0.5 | 1.27 (0.50‐3.18) | 0.6 |
| Death | 229 (3.03) | 177 (2.60) | 52 (6.77) | 2.61 (1.86‐3.67) | <0.0001 | 1.40 (0.97‐2.00) | 0.07 |
| MACNE | 217 (2.91) | 181 (2.70) | 36 (4.78) | 1.77 (1.28‐2.46) | 0.0006 | 1.40 (0.94‐2.10) | 0.1 |
| Bleeding outcomes | |||||||
| Major bleeding | 221 (2.98) | 189 (2.84) | 32 (4.28) | 1.49 (1.02‐2.18) | 0.04 | 1.15 (0.76‐1.73) | 0.5 |
| Bleeding hospitalization | 186 (2.50) | 159 (2.38) | 27 (3.60) | 1.49 (0.98‐2.27) | 0.06 | 1.04 (0.66‐1.63) | 0.9 |
CI indicates confidence interval; CNS, central nervous system; HR, hazard ratio; MACNE, major adverse cardiovascular and neurological events, including a composite of TIA, stroke, non‐CNS embolism, MI, or cardiovascular death; MI, myocardial infarction; NOAC, non–vitamin K antagonist oral anticoagulant; TIA, transient ischemic attack.
a
HR for inappropriately reduced‐dose subjects relative to appropriately standard‐dose subjects.